Stock AFT AFT PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings AFT Pharmaceuticals Limited

Equities

AFT

NZAFTE0001S4

End-of-day quote New Zealand S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
3 NZD -4.15% Intraday chart for AFT Pharmaceuticals Limited -2.91% -14.29%
01/05 AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV MT
24/04 New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 64% by 2026.
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
AFT PHARMACEUTICALS LIMITED Stock AFT Pharmaceuticals Limited
-14.29% 187M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.37% 699B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.07% 571B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.38% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.38% 326B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.70% 286B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.68% 236B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-12.43% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-3.33% 154B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. AFT Stock
  4. Ratings AFT Pharmaceuticals Limited